Literature DB >> 33075504

Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study.

Limin Wei1, Xin Cheng2, Yulong Luo1, Rongxuan Yang1, Zitong Lei1, Hongli Jiang3, Lei Chen4.   

Abstract

INTRODUCTION: Convincing evidence suggests that non-alcoholic fatty liver disease (NAFLD) is associated with insulin resistance and an increased risk of diabetes; however, the association between lean NAFLD and incident diabetes, and especially differences according to gender, have not been reported thus far. This study therefore aimed to investigate whether lean NAFLD and overweight/obese NAFLD confer the same excess risk of new-onset diabetes in both genders.
METHODS: Our longitudinal study was performed in 14,482 euglycaemic adults who had participated in a health checkup programme. Fatty liver was diagnosed by abdominal ultrasonography. The outcome of interest was incident diabetes.
RESULTS: Over the median 6.0 years of follow-up, 356 cases of diabetes were diagnosed. After adjusting for sociodemographic and other potential confounders, the fully adjusted HR (95% CI) for incident diabetes in lean NAFLD vs lean without NAFLD patients was 2.58 (95% CI: 1.68-3.97) in the total cohort. Corresponding HRs were 5.53 (95% CI: 2.30-13.30) and 2.02 (95% CI: 1.24-3.31) for women and men, respectively. Post-hoc analysis revealed that the relative risk for developing diabetes was similar between lean and overweight/obese NAFLD groups whether in the entire study population or in subgroups stratified by gender (all P> 0.05).
CONCLUSION: Lean NAFLD is indeed a risk factor for incident type 2 diabetes in both genders, although the effect appeared to be more pronounced in women than in men. Further investigations are now needed to obtain a better understanding of the natural history of NAFLD in lean subjects.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Gender differences; Lean non-alcoholic fatty liver disease; Obesity; Type 2 diabetes

Mesh:

Year:  2020        PMID: 33075504     DOI: 10.1016/j.diabet.2020.08.008

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  5 in total

Review 1.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

2.  Fatty liver index as a predictive marker for the development of diabetes: A retrospective cohort study using Japanese health check-up data.

Authors:  Atsushi Kitazawa; Shotaro Maeda; Yoshiharu Fukuda
Journal:  PLoS One       Date:  2021-09-20       Impact factor: 3.240

Review 3.  A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Paul P Manka; Eda Kaya; Ali Canbay; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2021-08-19       Impact factor: 3.199

Review 4.  Nonalcoholic fatty liver disease shows significant sex dimorphism.

Authors:  Xing-Yu Chen; Cong Wang; Yi-Zhou Huang; Li-Li Zhang
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

Review 5.  Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives.

Authors:  Diego García-Compeán; Emanuela Orsi; Ramesh Kumar; Felix Gundling; Tsutomu Nishida; Jesús Zacarías Villarreal-Pérez; Ángel N Del Cueto-Aguilera; José A González-González; Giuseppe Pugliese
Journal:  World J Gastroenterol       Date:  2022-02-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.